For the second year in a row, Mastercard ranks as the largest corporate sponsor of the Greater New York chapter of the Cystic Fibrosis Foundation (CFF). This year alone, Mastercard has raised more than $90,000 from the Great Strides walk, and supported other CFF events such as the…
News
Researchers at West Virginia University (WVU) are working to develop a vaccine against Pseudomonas aeruginosa, the highly treatment-resistant bacteria that are a frequent cause of chronic lung infection and damage in cystic fibrosis (CF) patients. P. aeruginosa is considered a serious health threat by the Centers for Disease Control (CDC) because of its…
Kalydeco (ivacaftor) by Vertex Pharmaceuticals has been approved in the European Union for children ages 1-2 with cystic fibrosis (CF) who carry at least one of nine mutations in the CFTR gene — G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R — that prevent the CFTR chloride channel from working properly. “For the first time, EU physicians can now treat the…
Treatment with a triple combination — the new CFTR corrector VX-659, together with tezacaftor and Kalydeco (ivacaftor) — significantly improved lung function and was well-tolerated by cystic fibrosis (CF) patients, ages 12 and older, with at least one F508del mutation in two Phase 3 studies, according to Vertex Pharmaceuticals. This…
Girls with cystic fibrosis (CF) reach puberty six to eight months later than healthy girls, about 16 percent of young females with CF encounter problems during sex, and 78 percent of these women would like to have children someday. These are among the key findings of an unprecedented survey conducted…
GEn1E Lifesciences has added to its development pipeline an investigational non-antibiotic, antibacterial agent for treatment of Pseudomonas aeruginosa infections in people with cystic fibrosis (CF). The company established an exclusive option agreement with the University of Maryland, Baltimore (UMB) to license patent rights over the MUC1-ecto-domain (MUC1-ED) compound, currently…
A protein toxin called Tse7 is used by Pseudomonas aeruginosa to kill neighboring bacteria, and may help explain why lung infections in cystic fibrosis patients are often dominated by a single P. aeruginosa strain, a new study reports. The research, “The Pseudomonas aeruginosa T6SS-VgrG1b spike is topped by…
Rice University researchers are using a virus that infects moths and magnetic nanoparticles to develop a new vehicle for the delivery of CRISPR/Cas9, a genome-editing tool, with high efficiency and tissue specificity in vivo. CRISPR/Cas9 has gained attention as a potential tool to correct genetic defects linked to diseases…
The European Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Orkambi (lumacaftor/ivacaftor) as a treatment for children ages 2-5 with cystic fibrosis (CF) due to F508del mutations, Vertex Pharmaceuticals announced. CHMP’s positive opinion will be taken into consideration by the European Medicines Agency, which will…
A new test was able to assess various properties of the mucus that accumulates in the lungs of people with cystic fibrosis and other pulmonary diseases, and may help to find treatments — or a combination of treatments — for CF patients that can make coughing a more viable way…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.